Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 12/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CEL | P19835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570286 | 0.98 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2RORCKMO | |
| SCHEMBL15569264 | 0.97 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2RORCALDH1A1 | |
| SCHEMBL15569786 | 0.93 | RORC (0.46) | TAS1R3TAS1R1TAS1R2RORCALDH1A1 | |
| SCHEMBL17323529 | 0.87 | KMO (0.49) | KMOPTGDR2GLACEL | |
| SCHEMBL15570771 | 0.86 | ALDH1A1 (0.57) | TAS1R3TAS1R1TAS1R2RORCALDH1A1 | |
| SCHEMBL17323530 | 0.85 | KMO (0.51) | KMOALDH1A1PTGDR2GLAHPGD | |
| SCHEMBL17323545 | 0.85 | KMO (0.51) | KMOALDH1A1PTGDR2GLAHPGD | |
| SCHEMBL17323537 | 0.85 | KMO (0.51) | KMOALDH1A1PTGDR2GLAHPGD | |
| SCHEMBL16981781 | 0.85 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2RORCALDH1A1 | |
| SCHEMBL15570620 | 0.85 | ALDH1A1 (0.55) | TAS1R3TAS1R1TAS1R2RORCKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2884981-B1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2884981-B1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-25 | — | — | US | disclosed |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-25 | — | — | US | disclosed |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-25 | — | — | US | disclosed |
| US-9745265-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745265-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745265-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| CN-104853757-A | 4-heteroaryl substituted benzoic acid compounds as ROR gamma T inhibitors and uses thereof | MERCK SHARP & DOHME | 2015-08-19 | — | — | CN | disclosed |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2884981-A2 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014028589-A2 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | RORB, RORA, RORC | TAS1R3 4722/4885TAS1R1 4534/4885TAS1R2 4705/4885 |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | TAS1R3 4722/4885TAS1R1 4534/4885TAS1R2 4705/4885 |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | TAS1R3 4722/4885TAS1R1 4534/4885TAS1R2 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.